GENE ONLINE|News &
R&D
Cybin’s Breakthrough: Psychedelic Depression Drug CYB003 Sustains 12-Month Symptom Remission in Major Depressive Disorder
2024-11-19
Key Trends in the Pharmaceutical Pipeline for 2024 — Part II: U.S. and China Compete for Top Position in the Global Drug Development Landscape
2024-10-23
JPMA on Japan’s Biotech Industry: Cancer, Cardiovascular, and Aging Lead Diseases; Antibody, Cell, and Gene Therapies Top the Innovation List
2024-10-17
Biogen and UCB Promising Phase-III Trial Data for Lupus; CAR T-Cell Therapy Another Autoimmune Treatment Avenue
2024-09-25
InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment
2024-09-04
Merck’s KEYTRUDA Fails in Early-Stage Lung and Skin Cancer Trials, Ends Two Phase 3 Studies
2024-08-30
The Latest in Alzheimer’s Research: Restoring Cognitive Function with Nanotech, Gene Therapy, and Enhanced Brain Gamma Oscillations
2024-08-16
LATEST
From Fabs to Labs: TSMC, Mayo Clinic, and the Next Wave of Bio-Digital Innovation in Phoenix
2025-07-17
A New Contender Rises: China’s Hengrui and Innovent Challenge Zepbound and Wegovy in Global Weight-Loss Drug Race
2025-07-16
